Biotechnology
Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class P...
2025-09-15 12:11
1777
Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc
Australian scientists who discovered how to "turn off" genes that make cancer cells grow are celebrating the next phase of development – with Pfizer's first in class KAT6 inhibitor PF-07248144 now moving to the next stages of clinical investigation. MELBOURNE, Australia, Sept. 15, 2025 /PRNewswi...
2025-09-15 12:06
1353
MGI Tech Introduces DNBSEQ-T7+: A Next-Generation 'Data Mining Machine' for Genomics
SHENZHEN, China, Sept. 15, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, announced the launch of the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for larg...
2025-09-15 11:53
1666
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
SINGAPORE and GUANGZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initi...
2025-09-15 08:00
1508
Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101
SHANGHAI and SUZHOU, China, Sept. 14, 2025 /PRNewswire/ -- Phrontline Biopharma , a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the com...
2025-09-15 08:00
1338
Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium
* 7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025). * The newly released results, based on clinical practices at several leading hospitals inChina, offer a comprehensive overview of the efficacy and safety of NEFE...
2025-09-15 07:45
4591
/C O R R E C T I O N -- Mars/
In the news release, Mars Snacking and Unreasonable Group Welcome Fourteen New Ventures to Unreasonable Food™, issued11-Sep-2025 by Mars over PR Newswire, we are advised by the company that the release has been updated to include the full 2025 Unreasonable Food cohort. The complete, corrected rel...
2025-09-13 06:14
4991
LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious ...
2025-09-12 20:00
1916
Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig
NANJING, China, Sept. 12, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in a Phase1b/II clinical trial (NCT07099430) evaluating Opamtistomig (LBL-024, PD-L1/4-1BB bispecifi...
2025-09-12 12:39
1605
The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration
SUZHOU, China, Sept. 12, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharm...
2025-09-12 09:51
1472
Zhimeng Biopharma's Investigational Drug Approved to Initiate Phase 2 Epilepsy Clinical Trial in China
SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, has recently received clinical trial approval from the Center for Drug Evaluation (CDE) ofChina's Nat...
2025-09-12 00:00
1702
GLOBAL FIRST "High-Definition Image": Decoding the "Code of Youth" - LivingPhoenix's POGMENT Collagen Breakthrough Fills Global Gap
CHENGDU, China, Sept. 11, 2025 /PRNewswire/ -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd. (hereinafter "LivingPhoenix Technology") announced that its independently developed POGMENT triple-helix biomimetic collagen has, for the first time in the world, achi...
2025-09-11 21:27
1647
GLOBAL FIRST "High-Definition Image": Decoding the "Code of Youth" - LivingPhoenix's POGMENT Collagen Breakthrough Bridges International Gap
CHENGDU, China, Sept. 11, 2025 /PRNewswire/ -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd., announced that its self-developed POGMENT triple-helix biomimetic collagen has, for the first time globally, achieved high-resolution molecular visualization of "coll...
2025-09-11 20:26
1536
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately$45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will sup...
2025-09-11 20:05
1744
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by ProfessorSudha Rao at QIMR Berghofer. In this ex vivo study, blood samples from Stage IV HER2-...
2025-09-11 20:00
2890
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
* Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb) *...
2025-09-11 14:56
1338
HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the"Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT Excellence Awards 2025, h...
2025-09-11 11:52
1486
Amaran Biotech Wins Asia-Pacific Biologics CDMO Excellence Award for "Best Fill-Finish"
50-Person Team Demonstrates Taiwan's Biotech Strength HSINCHU, Sept. 11, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was awarded the "Best Fill-Finish" at the 2025 Asia-Pacific Biologics CDMO Excellence Awards held inSingapore...
2025-09-11 10:00
2025
XingImaging in partnership with SynuSight was awarded a grant from The Michael J. Fox Foundation to support development of the α-synuclein PET tracer 18F-FD4 for Parkinson's disease
NEW HAVEN, Conn., Sept. 11, 2025 /PRNewswire/ -- XingImaging in partnership with SynuSight Biotech has received funding of$3.84M from The Michael J. Fox Foundation to conduct studies on18F-FD4, a specific α-synuclein (α-syn)-targeted PET tracer. Based on prior investigator-initiated trials, the ...
2025-09-11 05:06
967
Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale ...
2025-09-10 21:30
1132
Week's Top Stories
Most Reposted
Tonik raises US$12M Pre-Series C to scale capital-efficient lending in the Philippines
[Picked up by 318 media titles]
2025-12-04 10:15
Hyundai Motor Group and Air Liquide Advance Global Partnership to Accelerate Hydrogen Ecosystem
[Picked up by 311 media titles]
2025-12-04 16:00
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 310 media titles]
2025-12-10 10:00
Klook takes the lead among international travelers booking paid tours and activities in Japan
[Picked up by 309 media titles]
2025-12-04 13:12
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4492
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3656
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3644
PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results
2025-12-05 21:45
3466